Baird initiated coverage of Dianthus with an Outperform rating and $58 price target. Lead agent DNTH103 is entering Phase 2 trials for three autoimmune neuromuscular diseases – generalized myasthenia gravis, or gMG, multifocal motor neuropathy, or MMN, and chronic inflammatory demyelinating polyneuropathy, or CIDP – notes the analyst. The firm believes complement inhibitors will be a leading drug class for each of these three indications and believe DNTH103 is well positioned to become the “leading complement inhibitor for each indication.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Two new option listings on July 9th
- Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
- Dianthus initiated with an Overweight at Cantor Fitzgerald
- Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
- Dianthus announces FDA clearance to initiate Phase 2 trial of DNTH103